{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:45:13Z","timestamp":1782794713101,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Dalbavancin (DBV) is a long-acting lipoglycopeptide with activity against Gram-positive pathogens approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Its pharmacological profile supports use in infections requiring prolonged therapy, yet its role in osteomyelitis without implantable devices (OM-WoID) remains off-label. This study aims to describe real-world DBV use in a large tertiary care hospital, focusing on its effectiveness in OM-WoID. Methods: This is a monocentric, retrospective analysis including all patients receiving DBV at ASST Spedali Civili di Brescia, Italy, from April 2017 to July 2023. The statistical analysis focused on patients who received DBV for either ABSSSI or OM-WoID, with the latter transitioning to DBV after traditional daily intravenous therapy. Clinical, microbiological, and treatment data were extracted from electronic records and stored in REDCap. Effectiveness was defined as infection resolution or improvement; treatment failure encompassed clinical worsening, recurrence or suppressive therapy. Predictors of failure were identified through univariate and stepwise multivariate logistic regression. Results: During the study period, 157 patients (63.0% male; mean age 62.5 \u00b1 20 years) received at least one dose of DBV, predominantly for off-label indications (66.2%). Early discharge was the most common reason for switching to DBV (66.3%). Focusing specifically on patients treated for ABSSSI (53) and OM-WoID (43), treatment success was achieved in 81.1% of ABSSSI and 90.7% of OM-WoID cases. In the stepwise multivariate logistic regression, older age was independently associated with an increased risk of treatment failure (OR 1.07, 95% CI 1.01\u20131.13; p = 0.028), while the presence of multimorbidity significantly reduced the risk (OR 0.07, 95% CI 0.01\u20130.77; p = 0.029). Discussion: Our study offers a comprehensive real-world analysis of DBV use in both approved and off-label indications. Although current clinical experience with DBV remains limited, DBV emerges as a valuable step-down option for the management of invasive Gram-positive infections in our setting. Consistent with previous evidence, older age independently increased the risk of treatment failure, whereas multimorbidity appeared protective, likely due to selection bias and the more intensive monitoring, earlier interventions, and tailored management such patients often receive. Our results support a broader range of approved indications for DBV to allow earlier discharge and more efficient use of healthcare resources.<\/jats:p>","DOI":"10.3390\/antibiotics15070640","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:11:57Z","timestamp":1782785517000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-871X","authenticated-orcid":false,"given":"Giorgio","family":"Tiecco","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7861-4758","authenticated-orcid":false,"given":"Angelica","family":"Lenzi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4327-7305","authenticated-orcid":false,"given":"Federico","family":"Cesanelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Van Hauwermeiren","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3807-7766","authenticated-orcid":false,"given":"Francesco","family":"Rossini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7068-0732","authenticated-orcid":false,"given":"Alessio","family":"Sollima","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mul\u00e9","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lorenzotti","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Signorini","sequence":"additional","affiliation":[{"name":"Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-7804","authenticated-orcid":false,"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"},{"name":"Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-9100","authenticated-orcid":false,"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"},{"name":"Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"},{"name":"Department of Global Public Health, Karolinska Institute, 17177 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102473","DOI":"10.1016\/j.jiac.2024.07.013","article-title":"Dalbavancin for the treatment of bone and joint infections: A meta-analysis","volume":"31","author":"Almangour","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jame, W., Basgut, B., and Abdi, A. (2021). Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260539"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Guest, J.F., Esteban, J., Manganelli, A.G., Novelli, A., Rizzardini, G., and Serra, M. (2017). Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187792"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14787210.2021.1828865","article-title":"Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: A systematic review and meta-analysis","volume":"20","author":"Nava","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106746","DOI":"10.1016\/j.ijantimicag.2023.106746","article-title":"REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI","volume":"61","author":"Papavramidis","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agent Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","article-title":"A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis","volume":"53","author":"Leanza","year":"2025","journal-title":"Infection"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lovatti, S., Tiecco, G., Mul\u00e9, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., and Quiros-Roldan, E. (2023). Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071005"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"dlad044","DOI":"10.1093\/jacamr\/dlad044","article-title":"Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals","volume":"5","author":"Bai","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_16","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: A narrative review","volume":"27","author":"Fiore","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12941-022-00507-5","article-title":"Successful use of dalbavancin in the treatment of gram positive blood stream infections: A case series","volume":"21","author":"Evins","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC Guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jgar.2024.06.002","article-title":"Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry","volume":"38","author":"Zhanel","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ruiz-Sancho, A., N\u00fa\u00f1ez-N\u00fa\u00f1ez, M., Castelo-Corral, L., Mart\u00ednez-Marcos, F.J., Lois-Mart\u00ednez, N., Abdul-Aziz, M.H., and Vinuesa-Garc\u00eda, D. (2023). Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: Efficacy and safety. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1185602"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-024-04849-0","article-title":"Dalbavancin as suppressive therapy for implant-related infections: A case series with therapeutic drug monitoring and review of the literature","volume":"43","author":"Gachet","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gallerani, A., Gatti, M., Bedini, A., Casolari, S., Orlando, G., Puzzolante, C., Franceschini, E., Menozzi, M., Santoro, A., and Barp, N. (2023). Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111639"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Caselli, D., Mariani, M., Colomba, C., Ferrecchi, C., Cafagno, C., Trotta, D., Carloni, I., Dibello, D., Castagnola, E., and Aric\u00f2, M. (2024). Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing. Children, 11.","DOI":"10.3390\/children11010078"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cid\/ciy418","article-title":"Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group)","volume":"68","author":"Babitch","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2129566","DOI":"10.1001\/jamanetworkopen.2021.29566","article-title":"Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial","volume":"4","author":"Dinh","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Larkin, J., Foley, L., Timmons, S., Hickey, T., Clyne, B., Harrington, P., and Smith, S.M. (2025). How do people with multimorbidity prioritise healthcare when faced with tighter financial constraints? A national survey with a choice experiment component. BMC Prim. Care, 26.","DOI":"10.1186\/s12875-025-02738-9"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","first-page":"395","article-title":"Osteomyelitis: Diagnosis and Treatment","volume":"104","author":"Bury","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care-associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cardoso, T., Almeida, M., Friedman, N.D., Arag\u00e3o, I., Costa-Pereira, A., Sarmento, A.E., and Azevedo, L. (2014). Classification of healthcare-associated infection: A systematic review 10 years after the first proposal. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-40"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_36","unstructured":"R Core Team (2021). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:13:57Z","timestamp":1782792837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["antibiotics15070640"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15070640","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}